This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
where Ntotal is the constant number of particles throughout the decay process, which is equal to the initial number of A nuclides since this is the initial substance. If the number of non-decayed A nuclei is:
==== Usage in global industry ==== Direct oxidation of ethylene was patented by Lefort in 1931. This method was repeatedly modified for industrial use, and at least four major variations are known. They all use oxidation by oxygen or air and a silver-based catalyst, but differ in the technological details and hardware implementations. Union Carbide (currently a division of Dow Chemical Company) was the first company to develop the direct oxidation process. A similar production method was developed by Scientific Design Co., but it received wider use because of the licensing system – it accounts for 25% of the world's production and for 75% of world's licensed production of ethylene oxide. A proprietary variation of this method is used by Japan Catalytic Chemical Co., which adapted synthesis of both ethylene oxide and ethylene glycol in a single industrial complex. A different modification was developed Shell International Chemicals BV. Their method is rather flexible with regard to the specific requirements of specific industries; it is characterized by high selectivity with respect to the ethylene oxide product and long lifetime of the catalyst (3 years). It accounts for about 40% of global production. Older factories typically use air for oxidation whereas newer plants and processes, such as METEOR and Japan Catalytic, favor oxygen.
An extension of the WAG algorithm is used, with a new PhyML (WAG+Γ4) model taking into account of sites with different evolutionary rates. Qmaker and nQmaker (2021, 2022), programs with the ability to estimate time-reversible and nonreversible matrices from very large datasets quickly. Each provide a general matrix and 5 specialized matrices, for a total of 12 precalculated substitution matrices. Matrices using a selection of proteins based on structural relatedness, as proposed by Benner et al. (1994), Fan (2004), and Steven et al. (2004). Matrices using structural alignments of proteins instead of simple sequence alignment (6 separate publications). Matrices using known physiochemical parameters of amino acid residues (5 separate publications). For a list of more models (including irreversible i.e. asymmetric and/or specialized ones), see the documentation for recent bioinformatic software including IQ-Tree, PhyML, and RAxML.
On June 13, 2013, ESPN announced that they would end the broadcast of the ESPN 3D channel by the end of that year and would "...experiment with things like UHDTV." On June 26, 2013, Sharp announced the LC-70UD1U, which is a 70 in (180 cm) 4K Ultra HD TV. The LC-70UD1U is the world's first TV with THX 4K certification. On July 2, 2013, Jimmy Kimmel Live! recorded in 4K Ultra HD a performance by musical guest Karmin, and the video clip was used as demonstration material at Sony stores. On July 3, 2013, Sony announced the release of their 4K Ultra HD Media Player with a price of US$7.99 for rentals and US$29.99 for purchases. The 4K Ultra HD Media Player only worked with Sony's 4K Ultra HD TVs. On July 15, 2013, the CTA published CTA-861-F, a standard that applies to interfaces such as DVI, HDMI, and LVDS. The CTA-861-F standard adds support for several Ultra HD video formats and additional color spaces. On September 2, 2013 Acer announced the first smartphone, dubbed Liquid S2, capable of recording 4K video. On September 4, 2013, the HDMI Forum released the HDMI 2.0 specification, which supports 4K resolution at 60 fps. On the same day, Panasonic announced the Panasonic TC-L65WT600—the first 4K TV to support 4K resolution at 60 FPS. The Panasonic TC-L65WT600 has a 65 in (170 cm) screen, support for DisplayPort 1.2a, support for HDMI 2.0, an expected ship date of October, and a suggested retail price of US$5,999.
=== Class II === Class II hydrophobins have overall a more conserved amino acid sequence between the different types and, contrary to class I, they have short, regular inter-cysteine spacing. Opposite to class I, the class II hydrophobins monolayer formed at hydrophobic:hydrophilic interfaces is not fibrillar and it is not associated with formation of amyloid-structures, nor with large conformational changes. Nonetheless, high resolution atomic-force microscopy studies revealed the formation of a notable hexagonal repeating pattern over surfaces coated with the class II hydrophobin HBFI, meaning that these proteins are also able to form an ordered network in surface films. The crystal structures or HFBI and HFBII from Trichoderma reesei were the first class II hydrophobins to be determined.
Sources: en.wikipedia.org
mTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2. The two complexes localize to different subcellular compartments, thus affecting their activation and function. Upon activation by RHEB, mTORC1 localizes to the Ragulator-Rag complex on the lysosome surface where it then becomes active in the presence of sufficient amino acids.
=== Transcriptional modulation === Both human prohibitins have also been suggested to be localized in the cell nucleus and modulate transcriptional activity by interacting with various transcription factors, including nuclear receptors, either directly or indirectly. However, little evidence for nuclear targeting and transcription factor-binding of prohibitins has been found in other organism (yeast, plants, C. elegans, etc.), indicating that this may be a specific function in mammalian cells.
The Truman Show was a commercial success, grossing $264 million worldwide against a budget of $60 million. A Film4 critic stated that the film "allows Carrey to edge away from broad comedy", adding that it was "a hilarious and breathtakingly conceived satire". That same year, Carrey appeared as a fictionalized version of himself on the final episode of Garry Shandling's The Larry Sanders Show, in which he deliberately ripped into Shandling's character. In 1999, Carrey had the lead role in Man on the Moon. He portrayed comedian Andy Kaufman to critical acclaim and received his second Golden Globe in a row but again failed to be nominated for an Academy Award. In addition, he received his first Screen Actors Guild Award nomination for Best Actor.
Additionally, one trial aimed to assess its role in preventing actinic keratosis in organ transplant recipients. Further trials were pursued for the first two conditions, while results for the latter three were not published. Following the initial trials, research efforts centered on erythropoietic protoporphyria, and due to the epidemiology of the condition. Clinuvel secured orphan drug for afamelanotide in both the US and the EU by 2010. The first approval of afamelanotide came in May 2010 from the Italian Medicines Agency (AIFA, or Agenzia Italiana del Farmaco), followed by the European Medicines Agency (EMA) in January 2015. Both approvals were for the treatment of erythropoietic protoporphyria. The US Food and Drug Administration (FDA) granted approval in October 2019 for the use of afamelanotide as a medication to alleviate pain caused by sun exposure in individuals with erythropoietic protoporphyria. This decision was largely based on three trials involving 244 adults aged 18–74 across 22 sites in the US and Europe, which had a focus on pain-free hours in sunlight, outdoor hours under varying light conditions, and side effects. The FDA designated it as a first-in-class medication, meaning it had a novel mechanism different from previously approved medications. Between 2022 and 2023, trials were outlined to study the effects of afamelanotide on xeroderma pigmentosum and variegate porphyria, along with two additional trials exploring its impact on vitiligo. According to the register, as of April 2025, most of these trials are currently in the recruitment phase.
Sources: en.wikipedia.org
Regardless of changes leading to a semantic containment mechanism in new organisms, any novel biochemical systems still has to undergo a toxicological screening. XNA, novel proteins, etc. might represent novel toxins, or have an allergic potential that needs to be assessed.
Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products (e.g., biodegradable plastics, vegetable oil, biofuels), and environmental uses. For example, one application of biotechnology is the directed use of microorganisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, clean up sites contaminated by industrial activities (bioremediation), and also to produce biological weapons. A series of derived terms have been coined to identify several branches of biotechnology, for example:
An even more important event was the publication of a book by Regine Claβen-Bockhoff (2024) Die Pflanze: Morphologie, Entwicklung und Evolution von Vielfalt (The Plant: Morphology, Development and Evolution of Diversity). Like Kaplan's book, this book is very comprehensive (over a thousand pages) and beautifully illustrated (she worked with two illustrators), but unlike Kaplan's book, her book presents major conceptual innovations. Although, for the vegetative region, she accepts the categories of classical morphology, contrary to Kaplan, she recognizes that not all structures can be pressed into these categories. For flowers, she abandoned the classical framework altogether. Instead of interpreting the flower as a modified short shoot (as posited by classical morphology), she proposed that flowers are sporangia bearing units so that stamens and carpels are sporangiophores, which are considered 'de novo' structures not necessarily homologous with vegetative leaves. Rolf Sattler proposed an Articulation Morphology. It is based on the open growth of plants, which occurs through ramification that leads to articulation - the formation of articles between successive ramifications or after a single ramification. Thus, the plant is seen as an articulated whole, consisting of articles. The concept of the article encompasses the continuum between morphological categories and different levels of organization, from organ systems to organs, parts of organs and trichomes. Furthermore, it applies to all plants, from algae to bryophytes and vascular plants.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.